HomeNewsVirafin

Virafin

Jump to

Cadila: Vaccine opportunity unfolds

On conservative basis, for COVID vaccine opportunity, Cadila can at least add 16 per cent of FY21 sales revenue, on a full-year basis
Ideas For Profit | Cadila: COVID opportunity, complex pharma pipeline offer strong risk reward

Cadila’s stock was primed by a series of potential roll outs to meet the COVID-19 challenge. Beyond COVID, the company is steadily building up its injectable and biosimilars portfolio - the areas to look at for the longer term.
Zydus gets DCGI nod for emergency use of 'Virafin' in treating moderate COVID-19 cases

The company has claimed that 91.15 percent of COVID-19 patients treated with Virafin were RT-PCR negative by day 7.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Virafin

Cadila: Vaccine opportunity unfolds

Ideas For Profit | Cadila: COVID opportunity, complex pharma pipeline offer strong risk reward

Zydus gets DCGI nod for emergency use of 'Virafin' in treating moderate COVID-19 cases